Structural Basis of a Novel Agonistic Anti-OX40 Antibody

Agonistic antibodies targeting co-stimulating receptor OX40 on T cells are considered as important as (or complementary to) the immune checkpoint blockers in cancer treatment. However, none of these agonistic antibodies have reached the late stage of clinical development partially due to the lack of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Jiang, Xiaoyong, Gao, Han, Zhang, Fei, Zhang, Xin, Zhou, Aiwu, Xu, Ting, Cai, Haiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496217/
https://www.ncbi.nlm.nih.gov/pubmed/36139048
http://dx.doi.org/10.3390/biom12091209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496217/
https://www.ncbi.nlm.nih.gov/pubmed/36139048
http://dx.doi.org/10.3390/biom12091209

Ejemplares similares